Status and phase
Conditions
Treatments
About
Study will deteremine the MTD and evaluate the safety profile of oral lenalidomide on days 1-14 when combined with pemetrexed on day 1 of a 21 days cycle. Subjects will continue on study until documention of disease progression.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Any of the following laboratory abnormalities:
Any serious medical condition or psychiatric illness that places the subject at an unacceptable risk for study participation or would prevent the subject from signing the informed consent.
Prior history of malignancy (except basal cell or squamous cell carcinoma or carcinoma in situ of the breast) unless the subject has been free of disease for > 1 year.
Known brain or leptomeningeal disease (CT scan or MRI of the brain required only in case of clinical suspicion of central nervous system involvement).
More than one prior chemotherapy for advanced NSCLC.
Concurrent use of any other anti-cancer agents.
Any prior use of lenalidomide.
Pregnant or lactating females.
Prior > or = to grade 3 rash or any desquamating (blistering) rash while taking thalidomide.
Prior > or = to grade 3 allergic reaction/hypersensitivity to thalidomide.
Use of any standard/experimental anti-cancer drug therapy within 28 days of the initiation of study drug therapy.
Known Hepatitis C.
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal